Bill? Marty? Guido? Susan? Is anyone on the board paying attention?

Discussion in 'Bioventus' started by anonymous, Jan 12, 2019 at 2:53 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    We have watched Bioventus fail time and time again.

    Bioventus has not turned a profitable year for Essex Woodlands since inception in 2012. When is the board going to wake up and stop the embarrassment.

    Constant turnover has haunted the company with all the best reps, managers and VPs being forced out, or choosing to leave. This cycle has repeated over and over and over.

    When does Leigh Ann answer to the board for the terrible losses and inability to meet retention targets year after year? When does Leigh Ann get to explain the cost of 30-40% per year?

    Product launches have failed repeatedly. Scoliscore.... failed. Esaote Ultrasound.... failed. OsteoAmp.... failed. EMEA .... failed. Two critical IPO failures. First in 2014 and another in 2016.How many millions have been lost in the Pfizer BMP failure?

    When does Tony answer to the board for failures to take this company forward year after year?

    Bioventus continues to struggle with risky business processes that put reps in difficult compliance and ethical dilemmas. When does Anthony, Winnie and Jay answer to the board for failing create compliant business processes and decent standards?

    Loss of payer contracts and failure to secure a sustainable reimbursement structure for HA. Complete lack execution on the commercial side. When do John and David answer to the board?
     

  2. anonymous

    anonymous Guest

    Tough to read post bud sadly a lot of truth here.
     
  3. anonymous

    anonymous Guest

    All of the recent moves point to the company selling itself off and calling it a day.
     
  4. anonymous

    anonymous Guest

    ...tough to read but also a lot of false. Last year profitable, successful Durolane launch, growth in Gelsyn in 2018, looks like this year will be profitable, looks like this year we exceed budget , AAP exceeding goal multiple years .... maybe someone should ask when will you be accountable for your false comments
     
  5. anonymous

    anonymous Guest

    Profitable? That’s funny, do you have a source? Do you know the R&D costs incurred? How much did they lose on BMP? Durolane and Gelsyn?? Bioventus is literally rebating it away for 0 profit margins to get on formularies.

    Do you know the difference between margins and revenue? The only profit for HA is based on a Medicare loophole that will be shut down. This company cannot become profitable with high priced HA with crappy profit margins for private. The company is selling overpriced HA and relying on Medicare WAC rates to subsidize their heavy rebating to privates. SHADY business practice.

    What happens if or when rebates become illegal in the near future? The cheapest HA products will prevail. Bioventus cannot prevail on the HA revenues and margins. It’s an unsustainable model. This thing is a PUMP and DUMP and sell it off deal. The company knows WAC is going away. Look at the associates around you when the company needs to cut costs for the new reality. FDA working on making all BGS Class II which means any company can compete with Exogen for LIPUS. Look it up. Orthofix was sued for not meaning this. No products in this division that isn’t easily commoditized.
     
  6. anonymous

    anonymous Guest

    Fact is Bioventus funds itself by producing a 100 Exogen and selling it for 4,950. This will end soon. CPAP was just moved from Class III to class II a few months ago. This means a flood of competition can enter the market without footing millions for studies and driving down margins. This saves the government, payers and customers Millions.

    https://aasm.org/fda-reclassifies-positive-aiway-pressure-class-ii-medical-device/


    Here is a lawsuit on Orthofix for not disclosing to shareholders that the FDA is currently moving to reclassify all BGS as a Class II.

    https://www.prnewswire.com/news-releases/ofic-notice-rosen-law-firm-announces-investigation-of-securities-claims-against-orthofix-international-nv---ofix-300388113.html
     
  7. anonymous

    anonymous Guest


    More funny, do you have a source? Do you know RD costs,etc? And yes I do know the difference between margins and revenue - learned that in school. First you say we never made a profit and now your logic is things that may or may not happen in the future will cause it not to make a profit. If you are part of the company why don’t you leave if the past and the future is so bleak? If you are a competitor,too bad, as we are profitable and we are beating you. Sorry not sorry.
     
  8. anonymous

    anonymous Guest

    https://www.google.com/amp/s/seekingalpha.com/amp/article/3986068-key-problems-bioventus-ipo


    • The company has not made a profit since being founded in 2012, and economic conditions could dry up the investment funding it depends on.

    What does hitting a goal or revenue target have anything to do with profitability? The growth is coming from Medicare for HA which won’t last. The privates only play ball with heavy rebating which the company can’t profit off of.
     
  9. anonymous

    anonymous Guest

    let me explain it to you in simple words you may be able to understand. Revenue targets and expense targets are set in order to insure profit targets are met. If you achieve your revenue and manage your expenses to budget you make profit. It would appear based upon updates BV has done both this year. You are a fool so I will no longer try to help school you.
     
  10. anonymous

    anonymous Guest

    Just give up. You didn’t answer the question at all. You asp have no clue regarding other variables. You sound like the first year sales rep that thinks they have have it all figured out.

    Meeting a goal. Ha. Good one.
     
  11. anonymous

    anonymous Guest

    The EW board has no clue. Neither does Bioventus executive leadership.

    There’s a reason this company is a mess. It starts at the top.
     
  12. anonymous

    anonymous Guest

    look at the history and it’s easy to find the toxic common denominator that is holding this company back

    The CEO has been replaced
    The CFO has been replaced
    The VP of sales has been replaced.
    Training director has been replaced

    The VP of Human Resources has been around since day 1.

    Until LAS is out, this company will never attract and keep top talent and will never become “a leader in active orthobiologics”
     
  13. anonymous

    anonymous Guest

    Sad but very true.
     
  14. anonymous

    anonymous Guest

    yiu have no clue what you’re talking about... the facts which are not disputable.

    CFO left on own accord for a great oppty.
    VP Sales had a compliance violation that was not ignorable with a pattern.
    Training director left due bc of boss
    CEO I will give you... JA was a horrendous selection as his expertise is analytics not leadership.

    That does not all add up to LAS to blame. It’s u fortunate she is crucified for all of the decisions that are a result of many many other factors.

    Learn the facts bc your way off.
     
  15. anonymous

    anonymous Guest

    heard that FB left today. Its very sad since she has been such an asset to BV over the years.

    What does it say about the company when the Senior Manager of Market Insights bails?

    Will the company rehire this role? Or have they already given up on future acquisitions?
     
  16. anonymous

    anonymous Guest

    the new exogen process is completely fcked management has no understanding of the process. with all the new regulation and process changes do you really expect us to hit these quotas? don't think so.what percentage of reps hit quota last year? these new quota numbers are ridiculous. gelsyn and duroalne numbers are a joke. more work less pay every year. now the culture is completely gone to hell.

    i am working another job and taking the paychecks until BV finally crashes. im giving nothing more to this company while i focus on my new job. BV and david varner can eat a phenomenally fat dck.
     
  17. anonymous

    anonymous Guest

    Good to see the same person using the same profanity on 2 threads. Not sure what your obsession with male genitalia is but get some help.
     
  18. anonymous

    anonymous Guest


    Actually company is having a good month with far more reps exceeding quota for Exogen and HA than the last few months of 2018! Good work reps!!!
     
  19. anonymous

    anonymous Guest

    Yea fucking right, this is such BULLSHIT! No one on our team hit quota. BV corporate clowns posting fake news.
     
  20. anonymous

    anonymous Guest

    Looking at the numbers now. You are completely wrong. It’s a good first month for the company!